Slide 1: Company Overview April 2022
© 2020 Innate Pharma. All rights reserved. PARIS: IPH.PA NASDAQ: IPHA Company Overview April 2022
Slide 2: Disclaimer
This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document contains forward-looking statements. The use of certain words
Slide 3: A Leading Company in the Field of Innate Immunity
A Leading Company in the Field of Innate Immunity M A R S E I L L E F R A N C E R O C K V I L L E M A R Y L A N D Founded: 1999 Paris Euronext listing: 2006 Nasdaq listing: 2019 3 • Global, clinical-stage oncology-focused biotech company. • Scientific excellence in the field of innate immunity with
Slide 4: Scientific Innovation Drives Our Strategy
Drive near-term value with Lacutamab Advance our innovative R&D pipeline Build a sustainable business through partnerships 4 Scientific Innovation Drives Our Strategy We aim to harness our scientific know-how in innate immunity and antibody engineering to develop oncology products that improve the l
Slide 5: Strong Science + Strong Partnerships = Robust Pipeline
5 Strong Science + Strong Partnerships = Robust Pipeline Validated Science in high-impact publications Strong Track Record of Collaborations with industry and academia Robust Pipeline with innovative pre-clinical and clinical assets
Slide 6: Innate's Approach: Harnessing Innate Immunity in Cancer
Lymph node Blood vessel TUMOR Priming and activation (APCs and T cells) Trafficking of T cells to tumors Infiltration of T cells into tumors Effector innate immune response (phagocytosis, cytotoxicity) Cancer antigen presentation (DCs) Ampliication of the innate immune response (macrophages, NK, DCs
Slide 7: Our Robust Pipeline of Proprietary & Partnered Assets
Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Lacutamab KIR3DL2 Sézary Syndrome Preliminary Phase 2 data expected 2022 Mycosis Fungoides Early data presented Preliminary Phase 2 data expected 2022 PTCL (combo with GemOx) Phase 2 start H2 2021 PTCL (mono) Phase 1 start H2 2021
Slide 8: Driving Our Proprietary Portfolio
Driving Our Proprietary Portfolio
Slide 9: Lacutamab: Lead Proprietary Asset
9 Lacutamab: Lead Proprietary Asset • Lacutamab under development for the treatment of various forms of T-cell lymphomas (TCL) • Compelling Phase 1 data in Sézary syndrome (SS), published in Lancet Oncology • EMA PRIME and FDA Fast Track designations for SS patients who have received at least two pr
Slide 10: Development Informed by Target Expression
SEZARY SYNDROME • >90% of patients express target* • All tissues involved (skin, blood and lymph nodes) MYCOSIS FUNGOIDES • ~50% of patients express target* PERIPHERAL T-CELL LYMPHOMA • KIR3DL2 is expressed in multiple PTCL subtypes • ~50% of patients express target* ~80–200 patients1 2,200–4,000 pa
Slide 11: Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas
11 Developing New Standard of Care in KIR3DL2-Expressing T-Cell Lymphomas LACUTAMAB Mycosis Fungoides Expand potential beyond SS Explore impact of KIR3DL2 expression on clinical outcome Multiple trials to support PTCL Detecting early signal in relapsed population then expanding in earlier lines or i
Slide 12: Compelling Phase 1 Results in Sézary Syndrome
Compelling Phase 1 Results 12 FDA Fast Track Designation granted based on these results 1DLT = dose limiting toxicity 2AE = adverse event 3 MAVORIC trial: Mogamulizumab vs. vorinostat in previously-treated CTCL. Source: Kim et al, Lancet Oncology 2018 4LCT = large cell transformation 5 TTNT = Time-t
Slide 13: TELLOMAK Phase 2 Study in Two CTCL Subtypes
13 TELLOMAK Phase 2 Study in Two CTCL Subtypes Mycosis Fungoides (N~100) ≥ 2 prior systemic therapies Cohort 1 All comers, SS, must include mogalizumab as prior therapy Sézary Syndrome (N~60) ≥ 2 prior systemic therapies Cohort 2# KIR3DL2+ Simon 2 Stage All Comers* KIR3DL2+/- STUDY ENDPOINTS • Prima
Slide 14: Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort
14 Encouraging Preliminary Results in KIR3DL2-Expressing MF Cohort of TELLOMAK Trial LACUTAMAB * reported after data cut off (DCO) date, May 10, 2021. Bagot et al. ICML June 2021. Response rate reported after data cut off. CR: complete response, PR: partial response, uPR: unconfirmed partial respons
Slide 15: Initiating Data-Driven Strategy in PTCL
15 Initiating Data-Driven Strategy in PTCL 03 02 01 RELAPSED SETTING Highest unmet medical need; two-pronged approach: • Monotherapy (Phase 1b study in H2 2021) • Combination with: • GemOx (LYSA-sponsored Phase 2 KILT study in H2 2021); and • other SOC N O W FRONTLINE Driven by data in the relapsed
Slide 16: Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas
16 Developing a New Standard of Care Across KIR3DL2- Expressing T-Cell Lymphomas Sezary Syndome Mycosis Fungoides • Trial expanded (pivotal potential) • Fast Track & PRIME Designation • Preliminary data expected in 2022 (H2) • Advanced Cohort 2 to Stage 2 with earlier-than-expected efficacy signal •
Slide 17: Next-Generation Assets: NK Cell Engagers
Next-Generation Assets: NK Cell Engagers
Slide 18: NK Cells Offer Unique Cancer-Fighting Abilities
18 Tumor-infiltrating Natural Killer cells. Cózar et al., Cancer Discovery 2021 Multifunctional Natural Killer Cell Engagers targeting NKp46 trigger protective tumor immunity. Gauthier et al., Cell 2019 Harnessing innate immunity in cancer therapy. Demaria et al., Nature 2019 Identification, activat
Slide 19: ANKET: Innate's Proprietary NK Cell Engager Platform
19 ANKET™: Innate’s Proprietary NK Cell Engager Platform is a versatile, fit-for- purpose technology that is creating an entirely new class of tri- and tetra-specific molecules to induce synthetic immunity against cancer ANKET™ Harnesses NK cell effector functions against cancer cells, through the m
Slide 20: New Data from IPH6101/SAR443579, Lead ANKET Asset
New Data from IPH6101/SAR443579, Innate’s Lead ANKET™ Asset 20 Research collaboration with partner Sanofi; Phase 1/2 clinical trial underway First NKp46/CD16-based NK cell engager that targets CD123 on AML cells Uses Innate’s proprietary multi-specific antibody format Announced €7M milestone payment
Slide 21: CD123 Tri-specific SAR443579/IPH6101 Demonstrates Potent Antitumor Activity Against AML
21 CD123 tri-specific targeted SAR443579/IPH6101 Demonstrates Potent Antitumor Activity Against AML and Favorable Safety Profile ANKETTM AML: Acute Myeloid Leukemia, HR-MDS: Higher-Risk Myelodysplastic Syndromes, ADCC: antibody drug conjugate, NHP: non-human primates The first NKp46/CD16-based NK Ce
Slide 22: Optimal Efficacy Requires All Arms in Tetra-specific ANKET
22 Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors ANKETTM *ADCC-enhanced mAbTAg: Tumor antigen Progressing towards IND enabling studies Disseminated tumor modelsSolid tumor models
Slide 23: Different Receptors Have Different Effects on NK Cells
23 Adapted from Lanier, Nature Immunol 2008; Vivier et al., Science, 2004 Different Receptors have Different Effects on NK cells NKp46 CD3ζ, FcRγ #DAP10 NKG2D • NK cell activation + •cytotoxicity • NK cell activation +++ •cytotoxicity •cytokines and chemokines CD16 IL-2Rb IL-2Rg • Proliferation +++
Slide 24: Building a Sustainable Business
Building a Sustainable Business
Slide 25: Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams
Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells SCCHN: Squamous Cell Carcinoma of the Head and Neck SOC: Standard of Care 25 Monalizumab: Strategic Asset Providing Scientific Validation and Revenue Streams Positive COAST randomized Phase 2 trial; AstraZeneca planning a second Phase 3
Slide 26: Monalizumab: Early NSCLC
NSCLC: Non-small cell lung cancer; Chemo: chemotherapy; Unresect.:unresectable; Stg: stage 26 Monalizumab: Early NSCLC Phase 3 program underway, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC MONALIZUMAB Source: André, Vivier et al., Cell 2018 NSCLC Phase 3 in unresectable
Slide 27: Monalizumab: NSCLC
27 Monalizumab : NSCLC COAST: Phase 2 study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC NeoCOAST: open-label, randomized, Phase 2, multidrug platform study of neoadjuvant durvalumab alone or combined with novel agents in pa
Slide 28: Monalizumab: Head and Neck Cancer
R/M SCCHN: Relapsed/metastatic squamous cell carcinoma of the head and neck; PDx: anti-PD-1/L1; 1L: First line; 2L: second line; 3L: third line 28 Monalizumab: Head and Neck cancer Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated SCCHN MONALIZUMAB Source: And
Slide 29: Catalysts and Summary
Catalysts and Summary @ innate pharma
Slide 30: Key Newsflow Over the Next Years
30 Key Newsflow Over the Next 2 Years IST: Investigator Sponsored Trial; HNSCC: Squamous Cell Carcinoma of the Head and Neck; BP: Bullous Penphigoid; MF: Mycosis Fungoides; SS: Sezary Syndrome; PTCL: Peripheral T Cell Lymphoma; IND: Investigational New Drug 2 0 2 2 2 0 2 3 Data Readouts Clinical Pro
Slide 31: Early R&D Focus to Drive Value Through Later Stage Partnerships
31 Early R&D focus to drive value through later stage partnerships Cash position of €159.7 million* as of December 31, 2021 with runway into mid 2023 Lacutamab R&D pipeline Partnerships • TELLOMAK read-out with MF in 2021 and preliminary data for MF and SS in 2022 • Initiating monotherapy and combin
Slide 32: Thank You
PARIS: IPH.PA NASDAQ: IPHA © 2020 Innate Pharma. All rights reserved. THANK YOU www.innate-pharma.com
Slide 33: Appendix
Appendix & innate pharma
Slide 34: 2021 Financial Highlights
34 2021 Financial Highlights Licensing and collaborations: €12.1m • €7.4m for monalizumab (AZ) • €1.6m R&D costs sharing – IPH5201/avdoralimab (AZ) • €3.0m for IPH6101/SARSAR443579 (Sanofi) Government funding for research expenditures: • €10.3m 65% expenses related to R&D R&D expenses €47m: decrease
Slide 35: Putting Lacutamab Phase 1 Data into Clinical Context
35 Putting Lacutamab Phase 1 Data into Clinical Context Recent results in MF/Sézary patients LACUTAMAB Mogamulizumab Vorinostat Patient population Patients who received at least one prior systemic therapy Response rate MF/SS: 28% MF: 21% SS: 37% MF/SS: 5% MF: 7% Sézary: 2% Median progression-free su
Slide 36: Lacutamab in Mycosis Fungoides According to KIR3DL2 Expression
LACUTAMAB IN PATIENTS (PTS) WITH MYCOSIS FUNGOIDES (MF) ACCORDING TO KIR3DL2 EXPRESSION: EARLY RESULTS FROM THE TELLOMAK PHASE 2 TRIAL Presented at ICML (Jun2021) and EORTC (Oct2021) Clinicaltrials.gov: NCT03902184 LACUTAMAB
Slide 37: TELLOMAK: Multi-cohort International Open-label Phase 2 Trial
Tellomak : T-cell lymphoma anti-KIr3dl2 therapy A Multi-cohort International Open-label Phase 2 Trial Mycosis Fungoides ≥ 2 prior systemic therapies including biological agents Stage 1 (N=21) Stage 1 (N=18) Cohort # 2 KIR3DL2 ≥ 1% Cohort # 3 KIR3DL2 < 1% If N ≥3 responses If N ≥3 responses Lacutamab
Slide 38: Preliminary Results from Stage 1 of the MF Cohorts
PRELIMINARY RESULTS FROM STAGE 1 OF THE MF COHORTS Data cut-off (DCO): 10 May 2021 LACUTAMAB
Slide 39: Patient Characteristics
Patient characteristics Cohort 2 KIR3DL2 ≥ 1% (N=17) Cohort 3 KIR3DL2 < 1% (N=19) Age in years, Median (range) 59 (33 – 76) 60 (19 – 81) - Female - Male 6 (35%) 11 (65%) 3 (16%) 16 (84%) - Stage IB / II - Stage III / IV 12 (70%) 5 (30%) 17 (89%) 2 (11%) Blood involvement at baseline (B1) 7 (41%) 2 (
Slide 40: Response by Compartment Cohort 2 KIR3DL2 ≥ 1%
Response by compartment Cohort 2 – KIR3DL2 ≥ 1% Compartment Involved at baseline Responses Skin 17 1CR, 8PR, 2uPR Blood 7 4CR Lymph node 8 1PR Viscera 0 - N: number, CR: complete response, PR: partial response, uPR: unconfirmed partial response Skin (N = 17) uPR * reported after DCO date Data cut-of
Slide 41: Response by Compartment Cohort 3 KIR3DL2 < 1%
Response by compartment Cohort 3 – KIR3DL2 < 1% Compartmen t Involved at baseline Responses Skin 19 2 PR Blood 2 - Lymph node 6 - Viscera 0 - N: number, CR: complete response, PR: partial response Skin (N = 19) * reported after DCO date Data cut-off (DCO): 10 May 2021Clinicaltrials.gov: NCT03902184
Slide 42: Treatment Related Adverse Events
Treatment related adverse events* (at least 5%) Cohort 2 + 3 (N = 36) Any grade Grade 3 / 4 Asthenia 4 (11%) 0 Nausea 4 (11%) 0 Arthralgia 2 (6%) 0 Diarrhea 2 (6%) 0 Fatigue 2 (6%) 0 AEs leading to treatment discontinuation 1 (3%) 1 (3%)^ Serious adverse events 1 (3%) 1 (3%) ^ Fatal adverse events 0
Slide 43: Monalizumab R/M SCCHN: Updated Results from Phase 2 Trial
ESMO-IO 2020 Abstract 235 Poster 81P 43 Monalizumab R/M SCCHN: Updated Results from Phase 2 Trial Cohort 2 post platinum and post anti-PD-(L)1 (n=40) • Population with high medical need • R/M SCCHN post platinum and post anti-PD-(L)1 where no treatment options are currently approved globally. • Prom
Slide 44: IPH5201 & IPH5301: Targeting Immunosuppressive Tumor Microenvironment
• CD39 and CD73 are enzymes expressed on different cells in the TME • Promote immuno-suppression by degrading pro-inflammatory ATP into immunosuppressive adenosine • IPH5201: ongoing Phase 1 trial being conducted by AstraZeneca; evaluating IPH5201 in monotherapy or in combination with durvalumab +/-
Slide 45: IPH5201: Preclinical Data
Sources: Perrot et al., Cell Reports 2019 *2018 collaboration and option agreement with AstraZeneca IPH5201*: Preclinical Data Significant tumor responses observed in response to treatment with PD-1 inhibitors and ADCC-inducing antibodies, as well as with immunogenic chemotherapy, compared to respon
Slide 46: IPH5301: Preclinical Data
I P H 5 3 M E D I 9 4 4 7 C D 7 3 . 4 0 2 0 4 0 6 0 8 0 1 0 0 C D 4 + T c e l l s P r o li f e r a t io n r a t e ( n o r m a li z e d t o c o n t r o l) * * * * * * IPH5301: Preclinical Data IPH5301 more potent in restoring CD4+ and CD8+ T-cell proliferation in an ATP-suppression assay, than the mo